ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • July 16th, 2010 • Corgenix Medical Corp/Co • In vitro & in vivo diagnostic substances • Colorado
This Assignment and Assumption Agreement (“Agreement”) is made as of , 2010, by and among Elitech UK Limited, a private limited company organized under the laws of the United Kingdom (“Assignee”), Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), and Corgenix U.K. Ltd., a private limited company organized under the laws of the United Kingdom (“Corgenix U.K.” and, collectively with Corgenix, the “Assignors”).
MUTUAL CONFIDENTIALITY AGREEMENTMutual Confidentiality Agreement • July 16th, 2010 • Corgenix Medical Corp/Co • In vitro & in vivo diagnostic substances • Colorado
This Mutual Confidentiality Agreement (this “Agreement”), dated as of July 16, 2010, is entered into by and among Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), Wescor, Inc., a Utah corporation (“Wescor”), Elitech UK Limited, a private limited company organized under the laws of the United Kingdom (“Elitech UK” and, collectively with Elitech and Wescor, the “Elitech Group”), Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), and Corgenix U.K. Ltd., a private limited company organized under the laws of the United Kingdom (“Corgenix U.K.” and, collectively with Corgenix, the “Corgenix Group”).
COMMON STOCK PURCHASE AGREEMENT by and among CORGENIX MEDICAL CORPORATION FINANCIÈRE ELITECH SAS AND WESCOR, INC. July 12, 2010Common Stock Purchase Agreement • July 16th, 2010 • Corgenix Medical Corp/Co • In vitro & in vivo diagnostic substances • Nevada
THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into effective as of July 12, 2010 (the “Effective Date”), by and among Corgenix Medical Corporation, a Nevada corporation (the “Company”), Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), and Wescor, Inc., a Utah corporation and subsidiary of Elitech (“Investor”).
JOINT PRODUCT DEVELOPMENT AGREEMENTJoint Product Development Agreement • July 16th, 2010 • Corgenix Medical Corp/Co • In vitro & in vivo diagnostic substances • Colorado
This Joint Product Development Agreement (“Agreement”) is made and entered into on this 16th day of July, 2010 (“Effective Date”), by and between Corgenix Medical Corporation, a Nevada corporation (“Corgenix”), with its principal place of business at 11575 Main Street, Suite 400, Broomfield, Colorado 80020, and Financière Elitech SAS, a société par actions simplifiée organized under the laws of France (“Elitech”), with its principal place of business at 12-12bis, rue Jean Jaurès, 92800 Puteaux, France. Corgenix and Elitech are sometimes referred to in this agreement individually as a “Party” and, collectively, as the “Parties.”
ContractCorgenix Medical Corp/Co • July 16th, 2010 • In vitro & in vivo diagnostic substances • Nevada
THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS, HAVE BEEN TAKEN FOR INVESTMENT, AND MAY NOT BE SOLD OR TRANSFERRED OR OFFERED FOR SALE OR TRANSFER UNLESS A REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS WITH RESPECT TO SUCH SECURITIES IS THEN IN EFFECT, OR SUCH REGISTRATION UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS IS NOT REQUIRED.
